News & PR

ARISE-3 Study, the Phase 3 Clinical Trial of the New Drug RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTree

2019.02.14

ARISE-3 Study, the Phase 3 Clinical Trial of the New Drug RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTree

(if you want to view the body of article, click on the bottom link)

https://www.prnewswire.com/news-releases/arise-3-study-the-phase-3-clinical-trial-of-the-new-drug-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree-300793578.html

List

42개(1/3Page)

News & PR
No	Subject	Date
50	[RegeneRX] Letter to Stockholders-3-27-2025	2025.03.27
49	HLB테라퓨틱스, 신경영양성각막염 신약 후보물질 임상3상 환자 '추적관찰 종료'...'라이선스딜 속도'	2025.03.27
48	[RegeneRX] Letter to Stockholders 12-17-2024	2024.12.17
47	HLB테라퓨틱스, 합작법인에 'RGN-259' 권리 결집...기술수출 협상 속도	2024.08.21
46	[RegeneRX] Letter to Stockholders-8-12-2024	2024.08.12
45	HLB테라퓨틱스 'NK치료제', 美 평가기관서 최대 3조 가치평가	2024.08.12
44	[RegeneRX] Letter to Stockholders 4-2024 (final)	2024.04.04
43	[RegeneRX] Letter to Stockholders 12-2023	2023.12.27
42	[RegeneRX] Letter to Stockholders 7-10-2023 (final)	2023.07.10
41	“임상 3상 동시진행”…HLB테라퓨틱스, 안과질환 신약에 기대거는 이유	2023.05.17
40	HLB테라퓨틱스, 신경영양성각막염 美 임상 3상 환자 투여 시작	2023.04.13
39	[RegeneRX] Letter+to+Stockholders+4+2023+final	2023.04.11
38	HLB테라퓨틱스, SCI급 학술지에 NK치료제 3상 결과 발표	2023.01.02
37	HLB테라퓨틱스, FDA에 안구건조증 4번째 3상 사전논의 신청	2022.10.24
36	HLB테라퓨틱스, 신경영양성각막염 두번째 3상 계획 FDA 제출	2022.09.27
35	HLB테라퓨틱스, 신경영양성각막염(NK) 美·유럽 임상 3상 돌입	2022.07.18
34	HLB테라퓨틱스, 美 FDA에 안구건조증 치료제 Pre-BLA 제출	2022.02.03
33	에이치엘비테라퓨틱스, FDA와 Pre-BLA 미팅 확정	2021.12.17
32	에이치엘비테라퓨틱스, FDA에 안구건조증 치료제 Pre-BLA 미팅 신청	2021.11.25
31	HLB테라퓨틱스, 2021 AAO에서 희귀안과질환 '신경영양성각막염' 임상 3상 결과 발표	2021.10.29

HLB Companies

News & PR

ARISE-3 Study, the Phase 3 Clinical Trial of the New Drug RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTree